Regenxbio, Inc. [RGNX] Securities Class Action Lawsuit Update

• Case Name: Kuik v. Regenxbio, Inc. et al.
• Case No.: 8:26-cv-00611-DKC
• Jurisdiction: U.S. District Court, District of Maryland (Southern Division)
• Filed on: February 13, 2026
• Class Period: February 9, 2022 – January 27, 2026

Introduction

REGENXBIO, Inc. entered 2026 presenting itself as a company with momentum: gene therapy programs advancing, partnerships announced, and confidence radiating from management commentary. Then the illusion fractured.

On February 13, 2026, investors filed a federal securities class action in the U.S. District Court for the District of Maryland, alleging that REGENXBIO and several senior executives misled the market about the safety and viability of its gene therapy candidate RGX-111. According to the complaint, the company repeatedly touted positive trial data while allegedly concealing serious safety risks that ultimately forced regulators to intervene.

The reckoning arrived on January 28, 2026, when REGENXBIO disclosed that the FDA had placed RGX-111 on clinical hold following the discovery of an intraventricular CNS tumor in a treated patient. The stock fell nearly 18% in a single session. Investors say that drop was not bad luck but it was delayed truth.

“Most RGNX shareholders never file or join the class action, which means they miss out on potential recovery funds,” said Attorney Joesph Levi.

Backdrop and Business Context

REGENXBIO is a clinical-stage biotechnology company focused on gene therapies using its proprietary NAV adeno-associated virus (AAV) delivery platform. Its pipeline targets rare genetic diseases, many with few or no existing treatment options.

RGX-111, designed as a one-time gene therapy for severe Mucopolysaccharidosis Type I (MPS I), emerged as one of the company’s most closely watched programs. The therapy involved intracisternal administration, direct delivery into the central nervous system, an approach that carries both promise and inherent risk. During the class period, REGENXBIO positioned RGX-111 as a cornerstone asset. Management repeatedly emphasized biomarker activity, tolerability, and neurodevelopmental improvements, framing the program as both clinically encouraging and commercially meaningful.

Promises Made vs. Reality

Beginning in February 2022, REGENXBIO issued a series of press releases and earnings call statements highlighting what it described as positive interim data from RGX-111’s Phase I/II study. Executives emphasized that the therapy was “well tolerated,” repeatedly stating that no drug-related serious adverse events had been observed.

The company pointed to reductions in cerebrospinal fluid biomarkers, continued neurodevelopmental skill acquisition, and expanding patient cohorts. These statements persisted through 2023 and were reiterated even after the company publicly announced in November 2023 that it was de-prioritizing RGX-111 and pursuing ‘strategic alternatives.

According to the complaint, this optimism masked a darker internal reality. Plaintiffs allege that REGENXBIO was aware of serious safety risks associated with intracisternal AAV gene therapy including the potential for delayed genome integration and tumor formation, but failed to disclose those risks while continuing to promote RGX-111 as promising and safe.

Timeline of Alleged Misconduct and Disclosures

February 2022 – May 2023: REGENXBIO releases multiple updates describing RGX-111 as well tolerated, highlighting biomarker activity and neurodevelopmental gains, and stressing the absence of serious adverse events.

November 2023: The company announces a strategic pipeline reprioritization, effectively sidelining RGX-111 and seeking “strategic alternatives.” Management states the program will no longer contribute meaningfully to operating plans.

January 14, 2025: Despite prior deprioritization, REGENXBIO announces a partnership with Nippon Shinyaku, again referencing “very promising” RGX-111 Phase I/II results.

January 28, 2026: The FDA places RGX-111 on clinical hold after a routine MRI reveals an intraventricular CNS tumor in a treated patient. Preliminary analysis identifies AAV vector genome integration associated with proto-oncogene overexpression.

January 28, 2026 (Market Reaction): RGNX shares fall from $13.41 to $11.01, or approximately 17.8%, in a single-day decline.

Investor Harm and Market Reaction

Plaintiffs allege that REGENXBIO’s misstatements artificially inflated the company’s stock price throughout the class period, from February 9, 2022, through January 27, 2026.

When the clinical hold was disclosed, the market reaction was swift and unforgiving. Nearly one-fifth of the company’s market value evaporated in a day. Investors argue this drop directly reflects the market’s reassessment once the concealed safety risk became public.

The complaint ties loss causation squarely to the January 28 disclosure, asserting that earlier transparency would have materially altered investor decision-making.

Litigation and Procedural Posture

The action is brought on behalf of all investors who purchased or acquired REGENXBIO securities during the class period. Named defendants include: REGENXBIO, Inc., former President and CEO Kenneth T. Mills, current President and CEO Curran Simpson, and Chief Medical Officer Stephen Pakola, M.D.

The complaint asserts violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, alleging false statements, omissions, scienter, and control-person liability.

Plaintiffs contend that executives had access to non-public safety information and acted with at least reckless disregard for the truth while continuing to promote RGX-111’s prospects.

Shareholder Sentiment

Following REGENXBIO’s January 28, 2026 disclosure that the FDA had placed RGX-111 on clinical hold after a tumor was identified in a treated participant, external coverage focused on the seriousness of the regulatory action and the stock’s sharp decline. Reuters reported that the FDA placed clinical holds on two of the company’s experimental gene-therapy programs, while MarketWatch and other trade coverage noted that the news triggered a steep sell-off in REGENXBIO shares.

Analyst Commentary

External market commentary following the January 28, 2026 disclosure centered on regulatory and development risk. Reuters reported the FDA clinical hold after a tumor was found in one trial participant, and Seeking Alpha commentary noted that the January 2026 setbacks added risk to REGENXBIO’s platform and pipeline. MarketWatch also reported that REGENXBIO shares plunged after the FDA paused two drug-development programs.

SEC Filings & Risk Factors

Throughout the class period, REGENXBIO filed periodic reports with the SEC that included generalized risk disclosures regarding clinical development and regulatory uncertainty. Plaintiffs allege those disclosures failed to adequately warn investors about known, specific safety concerns related to RGX-111.

According to the complaint, boilerplate language could not substitute for disclosure of concrete risks allegedly known to management—particularly where those risks ultimately materialized in regulatory action.

Conclusion: Implications for Investors

The REGENXBIO case highlights a recurring fault line in biotech investing: the tension between hope and hazard. Gene therapy promises transformation but it also demands radical transparency.

For investors, the lawsuit underscores the importance of scrutinizing not just what companies say, but what they choose not to say. Safety signals delayed are risks compounded. When disclosure finally arrives, it rarely does so gently.

Now, shareholders are asking the courts to decide whether optimism crossed into deception.

How to Join the REGENXBIO, Inc. (RGNX) Class Action

• Confirm you purchased RGNX shares during the class period (February 9, 2022 – January 27, 2026)
• Review eligibility details
• Click here to check eligibility

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.